Literature DB >> 8234858

Disseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphoma.

H Sakamaki1, Y Onozawa, Y Yano, K Imai, T Sasaki, T Ibuka, N Funada, T Matsuda.   

Abstract

The authors report four adult patients with disseminated necrotizing leukoencephalopathy (DNL) following therapy for central nervous system (CNS) involvements of leukemia and lymphoma. Five to fourteen months after starting therapy with 30.6-62.5 Gy of whole brain irradiation and 120-500 mg of intrathecal methotrexate (MTX), DNL developed. Brain CT scans demonstrated a characteristic symmetrical white matter low density area. Furthermore, the brain CT scans disclosed tumorous lesions with contrast enhancement in three cases. In two of the three cases autopsy proved the tumorous lesions to be necrotic foci but not leukemic tumors. Post-mortem neuropathological studies of three patients disclosed characteristic features of DNL: multiple coagulative necrosis in the white matter with myelin degeneration, swollen axons, prominent calcification, and enlarged reactive astrocytes. Three of the four patients obviously received greater doses of whole brain irradiation and intrathecal MTX than patients who remained free from DNL after treatment with whole brain irradiation and/or MTX. Analysis of the etiological factors in this series underscores the prevailing danger of treatment for neoplastic CNS involvement with excessive doses of whole brain irradiation combined with intrathecal MTX.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234858

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  6 in total

1.  Disseminated necrotizing leukoencephalopathy following chemoradiation therapy for acute lymphoblastic leukemia.

Authors:  Ajaya R Pande; Kumiko Ando; Reiichi Ishikura; Yuki Nagami; Masayo Ogawa; Norihiko Kamikonya; Yumi Kaneda; Takakuni Tanizawa; Norio Nakao
Journal:  Radiat Med       Date:  2006-08

2.  Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors.

Authors:  Nobusada Shinoura; Yusuke Tabei; Ryozi Yamada; Kuniaki Saito; Masamichi Takahashi
Journal:  J Neurooncol       Date:  2007-12-12       Impact factor: 4.130

3.  Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.

Authors:  Alessandra Erbetta; Andrea Salmaggi; Angelo Sghirlanzoni; Antonio Silvani; Paolo Potepan; Andrea Botturi; Elisa Ciceri; Maria Grazia Bruzzone
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

4.  MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy.

Authors:  M Oka; S Terae; R Kobayashi; Y Sawamura; K Kudoh; K K Tha; M Yoshida; M Kaneda; Y Suzuki; K Miyasaka
Journal:  Neuroradiology       Date:  2003-05-22       Impact factor: 2.804

5.  Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas.

Authors:  Takuma Nomiya; Kenji Nemoto; Toshihiro Kumabe; Yoshihiro Takai; Shogo Yamada
Journal:  BMC Cancer       Date:  2008-01-16       Impact factor: 4.430

Review 6.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.